Novartis Q3 net income drops 70% to USD 1.2 billion
Bitget2026/10/27 06:01- Novartis' third-quarter 2026 net income fell 70% to USD 1.2 billion due to lower operating income and higher interest expense.
- Net sales rose to USD 14.52 billion, with volume growth partly offset by generic competition.
- A USD 1.9 billion partial impairment affected del-desiran; the drug missed its Phase III primary endpoint in myotonic dystrophy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays: Bloom Energy (BE.US) demand turning point is steeper than expected, rating raised to "Buy"
Barclays has upgraded Bloom Energy’s rating from "equal weight" to "overweight," setting a target price of $289.
Competitor turns supplier as the "new owner"! Bank of America: Marvell Technology's acquisition of Lumentum may prompt Cisco and Ciena to seek other sources
Bank of America analysts stated that Marvell Technology's acquisition of Lumentum may prompt Ciena and Cisco to diversify their optical component suppliers.
Goldman Sachs traders warn of an "invisible bear market": S&P 500 is only 3% away from its all-time high, but 60% of its constituent stocks have entered bear market territory.
The S&P 500 Index is only about 3% away from its latest record high, but 60% of the constituent stocks in this benchmark index are deeply entrenched in bear market territory.
Crypto prices
More
